|
Abstract To investigate the therapeutic effect of Xinfuning on cervical diseases by human papillomavirus (HPV) infected，and to study its effect on immunity of patients. Methods: 90 women with HPV infection-related cervical diseases were divided into the control group and study group from May 2016 to May 2017. The women in control group were treated by conventional therapy, and the women in study group were treated by Xinfuning except conventional therapy. The situation of T lymphocyte subsets, and the change of immunoglobulin and inflammatory cytokines of women in the two groups before and 1 month after treatment were recorded and compared, and the clinical efficacy and recurrence of HPV infected of women in the two groups after 6 months were also recorded. Results: Before treatment, the levels of CD3+ T cells, CD8+ T cells, CD4+ CD25+ T cells, Foxp3+ Tregs, IgA, IgG and IgM, C-reactive protein (CRP), tumor necrosis factor alpha (TNF-a), interferon(IFN) and interleukin-6 (IL-6) of women in both groups had no significant different(P>0.05). After treatment, all above indexes of women in both groups had improved, and the changes of all above indexes of women in control group were significant better than those of women in control group (P<0.05). 6 months after treatment, the incidence of HPV infected again of women in control group was significant lower than that of women in control group(P<0.05). Conclusion: Xinfuning can be used to treat HPV infection-related cervical diseases, which can decrease rate of HPV infected again of women by improving the levels of T lymphocyte subsets, immunoglobulin, and inflammatory cytokines.
|
|
|
|
|
|
